Skip to main content
Log in

Prämenstruelles Syndrom

Premenstrual syndrome

  • CME Weiterbildung • Zertifizierte Fortbildung
  • Published:
Gynäkologische Endokrinologie Aims and scope

Zusammenfassung

Das prämenstruelle Syndrom (PMS) ist durch wiederkehrende, zyklusabhängige Veränderungen mit psychischen, physischen und/oder sozialen Symptomen charakterisiert. Eine Sonderform stellt die sog. prämenstruelle dysphorische Störung (PMDS) dar. In jedem Zyklus ist 1 von 4 Frauen von prämenstruellen Beschwerden betroffen. Die Ätiologie ist multifaktoriell. Die Diagnosestellung erfolgt klinisch, da Serumhormonkonzentrationen nicht aufschlussreich sind. Psychiatrische und andere gynäkologische Erkrankungen sollten differenzialdiagnostisch ausgeschlossen werden. Die Therapie umfasst nichtpharmakologische Interventionen, Vitamine und Phytotherapeutika und Medikamente wie bestimmte orale Kontrazeptiva und serotonerge Antidepressiva. Letztere können kontinuierlich oder in der Lutealphase verabreicht werden. Langzeitstudien zur Sicherheit stehen jedoch aus.

Abstract

Premenstrual syndrome (PMS) involves physical, behavioural and mood changes that occur prior to the onset of menses. Severe dysphoric PMS is also referred to as premenstrual dysphoric disorder (PMDD). Clinically significant premenstrual symptoms occur in one in four menstruating women. The aetiology of PMDD is multifactorial. Laboratory testing is not useful for diagnosis. Symptoms should therefore be confirmed prospectively, and other diagnoses should be ruled out. Several effective treatment options exist: non-pharmacological treatment, vitamins and herbs. Pharmacological treatment includes oral contraceptives containing drospirenone, and serotonergic antidepressants, which can be applied continuously or intermittently. However, long-term studies on their efficacy and safety are warranted.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Abb. 1

Literatur

  1. Halbreich U, Endicott J, Schacht S, Nee J (1982) The diversity of premenstrual changes as reflected in the Premenstrual Assessment Form. Acta Psychiatr Scand 65: 46–65

    Article  PubMed  CAS  Google Scholar 

  2. World Health Organization (1987) The ICD-10 classification of mental, behavioral, and developmental disorders, 10th revision. Geneva, Switzerland

  3. American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders-IV, fourthed. American Psychiatric Association, Washington, D.C.

  4. Halbreich U, Borenstein J, Pearlstein T, Kahn LS (2003) The prevalence, impairment, impact, and burden of premenstrual dysphoric disorder (PMS/PMDD). Psychoneuroendocrinology (Suppl 3) 28: 1–23; Review

    Google Scholar 

  5. Kuhl H (2002) Sexualhormone und Psyche. Thieme, Stuttgart, S 18–22

  6. Halbreich U (2003) The etiology, biology, and evolving pathology of premenstrual syndromes. Psychoneuroendocrinology (Suppl 3) 28: 55–99; Review

    Google Scholar 

  7. Narrow WE, Rae DS, Robins LN, Regier DA (2002) Revised prevalence estimates of mental disorders in the United States: using a clinical significance criterion to reconcile 2 surveys‘ estimates. Arch Gen Psychiatry 59: 115–123

    Article  PubMed  Google Scholar 

  8. Rubinow DR, Smith MJ, Schenkel LA (2007) Facial emotion discrimination across the menstrual cycle in women with premenstrual dysphoric disorder (PMDD) and controls. J Affect Disord 104: 37–44

    Article  PubMed  Google Scholar 

  9. Pearlstein T, Steiner M (2008) Premenstrual dysphoric disorder: burden of illness and treatment update. J Psychiatry Neurosci 33: 291–301

    PubMed  Google Scholar 

  10. Steiner M, Haskett RF, Carrol BJ (1980) Premenstrual tension syndrome: the development of research diagnostic criteria and new rating scales. Acta Psychiatr Scand 62: 177–190

    Article  PubMed  CAS  Google Scholar 

  11. Freeman EW (2003) Premenstrual syndrome and premenstrual dysphoric disorder: definitions and diagnosis. Psychoendocrinology (Suppl 3) 28: 25–37

    Google Scholar 

  12. Halbreich U, Endicott J, Goldstein S, Nee J (1986) Premenstrual changes and changes in gonadal hormones. Acta Psychiatr Scand 74: 576–586

    Article  PubMed  CAS  Google Scholar 

  13. Facchinetti F, Genazzani AD, Martignoni E et al. (1993) Neuroendocrine changes in luteal function in patients with premenstrual syndrome. J Clin Endocrinol Metab 76: 1123–1127

    Article  PubMed  CAS  Google Scholar 

  14. Facchinetti F, Genazzani AD, Martignoni E et al. (1990) Neuroendocrine correlates of premenstrual syndrome: changes in the pulsatile pattern of plasma LH. Psychoneuroendocrinology 15: 269–277

    Article  PubMed  CAS  Google Scholar 

  15. Lewis LL, Greenblatt EM, Rittenhouse CA et al. (1995) Pulsatile release patterns of luteinizing hormone and progeserone in relation to symptom onset in women with premenstrual syndrome. Fertil Steril 64: 288–292

    PubMed  CAS  Google Scholar 

  16. Freeman EW, Rickels K, Sondheimer SJ, Polansky MP (1995) A double-blind trial of oral progesterone, alprazolam, and placebo in treatment of severe premenstrual syndrome. JAMA 274: 51–57

    Article  PubMed  CAS  Google Scholar 

  17. Huo L, Straub RE, Schmidt PJ (2007) Risk for premenstrual dysphoric disorder is associated with genetic variation in ESR1, the estrogen receptor alpha gene. Biol Psychiatry 62: 925–933

    Article  PubMed  CAS  Google Scholar 

  18. Schultz-Zehden B, Boschitsch E (2006) User experience with an oral contraceptive containing ethinylestradiol 30mug and drospirenone 3 mg (YASMIN®) in clinical practice. Treat Endocrinol 5: 251–256

    Article  PubMed  Google Scholar 

  19. Rapkin AJ (2005) New treatment approaches for premenstrual disorders. Am J Manag Care (Suppl 16) 11: S480–S491

    Google Scholar 

  20. Yonkers KA, Brown C, Pearlstein TB (2005) Efficacy of a new lowdose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol 106: 492–501

    PubMed  CAS  Google Scholar 

  21. Pearlstein TB, Bachmann GA, Zacur HA (2005) Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception 72: 414–421

    Article  PubMed  CAS  Google Scholar 

  22. Wyatt KM, Dimmock PW, Ismail KM (2004) The effectiveness of GnRHa with and without „add-back“ therapy in treating premenstrual syndrome: a meta analysis. BJOG 111: 585–593

    Article  PubMed  CAS  Google Scholar 

  23. Hahn PM, Van Vugt DA, Reid RL (1995) A randomized, placebo-controlled, crossover trial of danazol for the treatment of premenstrual syndrome. Psychoneuroendocrinology 20: 193–209

    Article  PubMed  CAS  Google Scholar 

  24. O’Brien PM, Abukhalil IE (1999) Randomized controlled trial of the management of premenstrual syndrome and premenstrual mastalgia using luteal phase-only danazol. Am J Obstet Gynecol 180: 18–23

    Article  Google Scholar 

  25. Ford O, Lethaby A, Mol B, Roberts H (2006) Progesterone for premenstrual syndrome. Cochrane Database Syst Rev 4: CD003415

    PubMed  Google Scholar 

  26. Dimmock PW, Wyatt KM, Jones PW (2000) Efficacy of selective serotonin-reuptake inhibitors in premenstrual syndrome: a systematic review. Lancet 356: 1131–1136

    Article  PubMed  CAS  Google Scholar 

  27. Wyatt KM, Dimmock PW, O’Brien PM (2002) Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst Rev 4: CD001396

    PubMed  Google Scholar 

  28. Shah NR, Jones JB, Aperi J et al. (2008) Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder: a meta-analysis. Obstet Gynecol 111: 1175–1182

    PubMed  CAS  Google Scholar 

  29. Berger CP, Presser B (1994) Alprazolam in the treatment of two subsamples of patients with late luteal phase dysphoric disorder: a double-blind, placebo-controlled crossover study. Obstet Gynecol 84: 379–385

    PubMed  CAS  Google Scholar 

  30. Harrison WM, Endicott J, Nee J (1990) Treatment of premenstrual dysphoria with alprazolam. A controlled study. Arch Gen Psychiatry 47: 270–275

    PubMed  CAS  Google Scholar 

  31. Smith S, Rinehart JS, Ruddock VE (1987) Treatment of premenstrual syndrome with alprazolam: results of a double-blind, placebo-controlled, randomized crossover clinical trial. Obstet Gynecol 70: 37–43

    PubMed  CAS  Google Scholar 

  32. Rickels K, Freeman E, Sondheimer S (1989) Buspirone in treatment of premenstrual syndrome. Lancet 1: 777

    Article  PubMed  CAS  Google Scholar 

  33. Andersch B (1983) Bromocriptine and premenstrual symptoms: a survey of double blind trials. Obstet Gynecol Surv 38: 643–646

    Article  PubMed  CAS  Google Scholar 

  34. Wang M, Hammarback S, Lindhe BA (1995) Treatment of premenstrual syndrome by spironolactone: a double-blind, placebocontrolled study. Acta Obstet Gynecol Scand 74: 803–808

    Article  PubMed  CAS  Google Scholar 

  35. Wyatt KM, Dimmock PW, Jones PW (1999) Efficacy of vitamin B-6 in the treatment of premenstrual syndrome: systematic review. BMJ 318: 1375–1381

    PubMed  CAS  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to P. Stute.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Stute, P., Kiesel, L. Prämenstruelles Syndrom. Gynäkologische Endokrinologie 6, 241–248 (2008). https://doi.org/10.1007/s10304-008-0280-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10304-008-0280-7

Schlüsselwörter

Keywords

Navigation